SEED Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Lead Oncology Asset RBM39 Degrader and Enters Strategic Transactions with New Investors
MWN-AI** Summary
SEED Therapeutics Inc., a biotechnology firm specializing in targeted protein degradation, has celebrated significant regulatory and financial developments. On January 28, 2025, the company announced that the U.S. Food and Drug Administration (FDA) granted Rare Pediatric Disease and Orphan Drug designations to its lead oncology asset, ST-01156, a molecular glue designed to degrade RBM39, an RNA splicing factor associated with several solid tumors. This designation not only recognizes the potential of ST-01156 to address critical unmet needs in oncology but also positions SEED to acquire an FDA priority review voucher upon approval, which can expedite the drug’s path to market.
SEED is preparing to file an Investigational New Drug (IND) application for ST-01156 in the first half of 2025, marking a pivotal moment in the company’s transition to a clinical-stage entity. Dr. Lan Huang, Co-founder and CEO, highlighted the importance of this achievement in the company’s four-year journey toward bringing innovative therapies to market.
Additionally, SEED announced a strategic transaction involving its largest shareholder, BeyondSpring Inc., which will sell a portion of its Series A-1 Preferred Shares while retaining approximately 14.4% of SEED's outstanding shares. This move aims to diversify SEED's shareholder base and align its capital structure with institutional investor expectations, thereby enhancing opportunities for future growth.
With these advancements, SEED Therapeutics is well-positioned to pursue further clinical development and maintain its innovative edge in targeted protein degradation therapies. The company’s commitment to addressing significant medical needs in oncology and neurodegeneration is bolstered by its robust pipeline and collaborations with major pharmaceutical firms like Eli Lilly and Eisai.
MWN-AI** Analysis
SEED Therapeutics Inc.’s recent FDA designations for its lead asset, ST-01156, present an intriguing investment opportunity in the biotechnology sector. By receiving both Rare Pediatric Disease and Orphan Drug designations, SEED is well-positioned to expedite the clinical development of ST-01156, a molecular glue targeting the RBM39 RNA splicing factor, known for its potential effectiveness in solid tumors. These designations may also lead to significant financial advantages, including the potential acquisition of a priority review voucher, which can be an asset for monetizing regulatory milestones.
With plans for an IND application submission in the first half of 2025, investors should closely monitor SEED's pipeline advancements, particularly as the company transitions into clinical-stage operations. Successful navigation through this phase will be crucial, not just for the approval of ST-01156 but also for further validating SEED’s RITE3™ platform's efficacy, an emerging tool in targeted protein degradation.
Moreover, BeyondSpring's strategic transactions to diversify shareholder base could bolster institutional interest in SEED, further stabilizing its capital structure. Maintaining approximately 14.4% ownership post-sales demonstrates BeyondSpring's commitment, which may instill confidence among existing and potential investors.
The broader context of oncology therapies targeting unmet medical needs enhances SEED's appeal. The role of RBM39 in various cancers, combined with SEED’s expertise and collaborations with big pharma like Eli Lilly, strengthens the company's stock potential, especially during a time when targeted therapies are gaining favor.
Investors should consider the long-term implications of these advancements while remaining vigilant about market risks inherent in biotech investment. Overall, SEED Therapeutics represents a potentially compelling investment case, especially for those seeking exposure in the growing field of oncology and rare disease therapies.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
KING OF PRUSSIA, Pa., Jan. 28, 2025 (GLOBE NEWSWIRE) -- SEED Therapeutics Inc. (“SEED”), a biotechnology company pioneering the discovery of molecular glues for targeted protein degradation (TPD) using its proprietary RITE3™ platform, today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease and Orphan Drug designations to SEED’s ST-01156 molecular glue. This novel agent degrades RBM39, an RNA splicing factor implicated in multiple mechanism-targeted solid tumor indications.
SEED is advancing ST-01156 toward an Investigational New Drug (IND) application, with an expected IND filing in the first half of 2025. The Rare Pediatric Disease designation positions SEED to potentially receive an FDA priority review voucher upon approval of ST-01156.
SEED also announced that its largest shareholder, BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring”), has entered into definitive agreements to sell a portion of its Series A-1 Preferred Shares of SEED. Upon completion of the transactions, BeyondSpring is expected to retain approximately 14.4% of SEED’s outstanding shares.
Pioneering Progress in Targeted Protein Degradation
“SEED is rapidly transitioning into a clinical-stage company, with the planned IND filing in the next few months for ST-01156, our novel and potentially best-in-class RBM39 degrader. This marks a significant milestone in our four-year journey to bring innovative therapies to patients,” said Dr. Lan Huang, Co-Founder, Chairman, and CEO of SEED and BeyondSpring. “RBM39 is a validated target to address cancers with high unmet medical needs, as highlighted in a recent Nature Reviews Drug Discovery article. At SEED, we are committed to improving patient outcomes through pioneering science and rational drug development.”
FDA Recognition and Strategic Growth
“The FDA’s Rare Pediatric Disease and Orphan Drug designations for ST-01156 represent an important milestone, recognizing its potential to address significant unmet needs in rare oncology indications,” said Jackson Tai, Board Member of SEED. “These designations may help expedite and reduce the cost of developing, approving, and commercializing this therapeutic agent.”
Tai added: “The transactions announced today will diversify SEED’s shareholder base. We believe this is a key step in ensuring that our capital structure and ownership distribution align with institutional investor expectations. SEED is now better positioned to pursue key initiatives, including advancing its clinical pipeline, extending its capital markets options, and maintaining its leadership in the field of targeted protein degradation.”
About SEED Therapeutics
SEED Therapeutics is an innovative biotech company focused on discovering and developing targeted protein degradation (TPD) therapeutics, with the mission to transform the treatment of diseases that currently have limited or no treatment options. Leveraging its cutting-edge RITE3™ platform, SEED is at the forefront of molecular glue-based TPD, addressing diseases in oncology and neurodegeneration. Through active collaborations with Eli Lilly and Company and Eisai Co., Ltd., and backed by a comprehensive intellectual property portfolio, SEED has built a robust pipeline of novel drug candidates now approaching clinical development. Visit www.seedtherapeutics.com to learn more.
About BeyondSpring
BeyondSpring is a global clinical-stage biopharmaceutical company advancing innovative therapies to improve clinical outcomes for patients with high unmet medical needs. BeyondSpring is advancing its first-in-class lead asset, Plinabulin, into late-stage clinical development as a direct anti-cancer agent in non-small cell lung cancer (NSCLC) and other cancer indications. Plinabulin binds to a differentiated pocket in tubulin, distinct from other tubulin binders, and is a potent inducer of dendritic cell maturation, which activates both adaptive and innate immunity. In combination with docetaxel, Plinabulin has demonstrated significant overall survival benefits compared to docetaxel alone in second- and third-line NSCLC with EGFR wild type ( Lancet Respir Med 2024). Additionally, Plinabulin has shown a significant reduction in severe neutropenia across multiple clinical studies. BeyondSpring’s pipeline also includes three preclinical immuno-oncology assets. Visit www.beyondspringpharma.com for more information.
Investor Contact:
IR@seedtherapeutics.com
Media Contact:
PR@seedtherapeutics.com
FAQ**
How will the sale of a portion of Series A-1 Preferred Shares by BeyondSpring Inc. (BYSI) affect its overall influence on SEED Therapeutics’ strategic direction and decision-making in the near future?
With the Rare Pediatric Disease designation for ST-01156, how might BeyondSpring Inc. (BYSI) leverage this status to enhance its investment appeal to institutional investors?
What specific measures is SEED Therapeutics taking to ensure that the transition into a clinical-stage biotech aligns with the expectations of BeyondSpring Inc. (BYSI) and other shareholders?
How does SEED Therapeutics plan to utilize the financial and strategic support from BeyondSpring Inc. (BYSI) in advancing its pipeline and clinical initiatives, especially with the upcoming IND filing for ST-01156?
**MWN-AI FAQ is based on asking OpenAI questions about BeyondSpring Inc. (NASDAQ: BYSI).
NASDAQ: BYSI
BYSI Trading
6.29% G/L:
$1.69 Last:
26,335 Volume:
$1.65 Open:
